PEPTIDESTAT
ApprovedClinical / approved drugIntravenousEvidence 4/5

Sincalide

Also known as: Kinevac, CCK-8

Sincalide is the synthetic C-terminal octapeptide of cholecystokinin that activates CCK receptors to stimulate gallbladder contraction, sphincter of Oddi relaxation and pancreatic secretion.

Read guideBuy / compare source
Sincalide
Drug class
Cholecystopancreatic-gastrointestinal hormone analog (diagnostic agent)
Primary targets
Cholecystokinin receptor (CCK-A / CCK1), Cholecystokinin receptor (CCK-B / gastrin)
Dose reference
Reference diagnostic doses (not a recommendation): 0.02 mcg/kg IV over 30-60 seconds, or a 0.12 mcg/kg infusion over ~50-60 minutes; per the Kinevac label.
Half-life
Very short; serum half-life roughly 2.5 minutes per the label (volunteer studies near 1.3 minutes)
Developer / origin
Bracco Diagnostics Inc. (Kinevac)
Reference year
1976
Evidence score
4/5 - Approved diagnostic with standardized methodology evidence

Approved uses

  • Stimulation of gallbladder contraction for diagnostic imaging or to obtain a duodenal-aspirate bile sample
  • Stimulation of pancreatic secretion in combination with secretin for duodenal-aspirate analysis
  • Acceleration of barium meal transit through the small bowel
Evidence 4/5

Approved diagnostic with standardized methodology evidence

Sincalide (Kinevac) is FDA-approved since 1976 as an intravenous diagnostic agent, with a well-defined mechanism and peer-reviewed methodology trials establishing optimal infusion protocols and gallbladder ejection fraction normal values.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • FDA-approved label (DailyMed/accessdata) defining indications, dosing, pharmacokinetics and warnings
  • Multicenter Journal of Nuclear Medicine study (Ziessman 2010) establishing a 60-minute infusion protocol and 38% lower limit of normal GBEF
  • Interdisciplinary consensus recommendations for cholecystokinin-cholescintigraphy
  • Evidence supports only controlled diagnostic use, not therapeutic or chronic dosing

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Sincalide guides

Read the matching guide or adjacent research pages for more context.

Sincalide Peptide: Kinevac (CCK-8), Uses and Safety LimitsSincalide is the FDA-approved synthetic CCK-8 peptide used as a short-acting intravenous diagnostic to stimulate gallbladder contraction and pancreatic secretion.Abaloparatide Peptide: Tymlos, PTHrP Analog Uses and Safety LimitsAbaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Bivalirudin Peptide: Angiomax Direct Thrombin Inhibitor GuideBivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Larazotide

Larazotide acetate, AT-1001

2/5
Clinical / approved drugInvestigational

An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.

DetailsGuide

Lanreotide

Somatuline Depot, Somatuline Autogel

5/5
Clinical / approved drugApproved

Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.

DetailsGuide

Teriparatide

Forteo, Bonsity, PTH 1-34

4/5
Clinical / approved drugApproved

Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.

DetailsGuide
4/5
Clinical / approved drugApproved

Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.